Market News / Story
Pharvaris (PHVS) Phase 3 Shows Deucrictibant IR Met All Endpoints in HAE
·
Pharvaris said RAPIDe-3 met its primary and all 11 secondary endpoints for oral deucrictibant IR in HAE attacks, with rapid symptom control and no safety signals. An NDA is under FDA review with a PDUFA target date of Apr. 23, 2027. Material Details #DetailAI Analyst View1RAPIDe-3 met primary endpointPivotal efficacy outcome de-risks the on-demand HAE program.2All 11 secondary endpoints metBroad clinical benefit supports potential approval and uptake.3Published in The…